GlassScriptPhysician profile
John Woo Lee
NPI 1053336057
$12,471.67
in general payments reported to CMS, 2019-2025
31 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $3,810 · 2021: $486 · 2022: $690 · 2023: $2,791 · 2024: $2,559 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,883 · Consulting Fee: $1,250 · Travel and Lodging: $1,093 · Education: $38.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,883.37 |
| Consulting Fee | $1,250.00 |
| Travel and Lodging | $1,092.77 |
| Education | $38.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $5,864.72 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $2,671.17 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Abbott Laboratories | $1,092.77 | 2024 | Accent |
| Genzyme Corporation | $582.36 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.19 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $287.88 | 2019-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $174.04 | 2021-2023 | Dupixent |
| Amgen INC. | $145.81 | 2021-2023 | Tezspire |
| Inari Medical, INC. | $144.07 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $137.89 | 2023-2025 | Glassia |
| Grifols USA, LLC | $134.60 | 2019-2025 | Prolastin-C Liquid |
| Penumbra, INC. | $122.31 | 2023 | Indigo System |
| Insmed, INC. | $109.53 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $99.23 | 2019-2024 | Yupelri |
| Boston Scientific Corporation | $93.85 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $89.63 | 2019 | |
| Philips North America LLC | $68.32 | 2019-2025 | Vest Therapy Und |
| United Therapeutics Corporation | $46.75 | 2023-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $42.49 | 2025 | Yupelri |
| Verona Pharma, INC. | $34.32 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $33.29 | 2022 | |
| Pulmonx Corporation | $30.25 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Shire North American Group INC | $28.50 | 2019 | |
| Electromed, INC. | $27.95 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $20.02 | 2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $18.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.12 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.40 | 2023 | |
| Advanced Respiratory, INC | $15.34 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.23 | 2019 | |
| Janssen Biotech, INC. | $12.96 | 2024 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.